Business Description
Morepen Laboratories Ltd
ISIN : INE083A01026
Compare
Compare
Traded in other countries / regions
500288.India IPO Date
1999-11-24Description
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.1 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | 0.16 | |||||
| Interest Coverage | 31.88 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 8.39 | |||||
| Beneish M-Score | -2.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.1 | |||||
| 3-Year EBITDA Growth Rate | 5.4 | |||||
| 3-Year EPS without NRI Growth Rate | -4.4 | |||||
| 3-Year Book Growth Rate | 20.6 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.25 | |||||
| 9-Day RSI | 67.65 | |||||
| 14-Day RSI | 62 | |||||
| 6-1 Month Momentum % | 73.44 | |||||
| 12-1 Month Momentum % | 96.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.69 | |||||
| Quick Ratio | 1.99 | |||||
| Cash Ratio | 0.5 | |||||
| Days Inventory | 84.06 | |||||
| Days Sales Outstanding | 63.16 | |||||
| Days Payable | 91.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.4 | |||||
| Shareholder Yield % | -0.1 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 37.08 | |||||
| Operating Margin % | 9.64 | |||||
| Net Margin % | 7.49 | |||||
| FCF Margin % | -0.45 | |||||
| ROE % | 14.34 | |||||
| ROA % | 9.73 | |||||
| ROIC % | 12.74 | |||||
| ROC (Joel Greenblatt) % | 25.37 | |||||
| ROCE % | 19.38 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 33.78 | |||||
| PE Ratio without NRI | 33.78 | |||||
| Shiller PE Ratio | 77.45 | |||||
| Price-to-Owner-Earnings | 107.81 | |||||
| PEG Ratio | 2.91 | |||||
| PS Ratio | 2.53 | |||||
| PB Ratio | 4.23 | |||||
| Price-to-Tangible-Book | 4.67 | |||||
| Price-to-Operating-Cash-Flow | 59.78 | |||||
| EV-to-EBIT | 25.16 | |||||
| EV-to-EBITDA | 22.1 | |||||
| EV-to-Revenue | 2.67 | |||||
| EV-to-FCF | -578.9 | |||||
| Price-to-Projected-FCF | 22.23 | |||||
| Price-to-DCF (Earnings Based) | 1.62 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.61 | |||||
| Price-to-Graham-Number | 2.65 | |||||
| Price-to-Net-Current-Asset-Value | 7.33 | |||||
| Earnings Yield (Greenblatt) % | 3.98 | |||||
| FCF Yield % | -0.17 | |||||
| Forward Rate of Return (Yacktman) % | 10.61 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Morepen Laboratories Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 17,522.712 | ||
| EPS (TTM) (₹) | 2.54 | ||
| Beta | 1.32 | ||
| Volatility % | 48.22 | ||
| 14-Day RSI | 62 | ||
| 14-Day ATR (₹) | 3.150404 | ||
| 20-Day SMA (₹) | 79.306 | ||
| 12-1 Month Momentum % | 96.09 | ||
| 52-Week Range (₹) | 38.55 - 100.9 | ||
| Shares Outstanding (Mil) | 547.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Morepen Laboratories Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Morepen Laboratories Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Morepen Laboratories Ltd Frequently Asked Questions
What is Morepen Laboratories Ltd(NSE:MOREPENLAB)'s stock price today?
The current price of NSE:MOREPENLAB is ₹88.47. The 52 week high of NSE:MOREPENLAB is ₹100.90 and 52 week low is ₹38.55.
When is next earnings date of Morepen Laboratories Ltd(NSE:MOREPENLAB)?
The next earnings date of Morepen Laboratories Ltd(NSE:MOREPENLAB) is 2025-01-31 Est..
Does Morepen Laboratories Ltd(NSE:MOREPENLAB) pay dividends? If so, how much?
Morepen Laboratories Ltd(NSE:MOREPENLAB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers